Literature DB >> 1722392

Haemangiopericytoma--Queensland Radium Institute experience and a review of the literature.

V A Ahern1, S J Roberts.   

Abstract

We report the presenting clinical characteristics, management, relapse patterns and survival of 17 patients with haemangiopericytoma treated at the Queensland Radium Institute, Australia from 1962 to 1989. Twelve patients were referred at the time of first diagnosis and were treated with curative intent. Three patients were treated with palliative intent when referred following initial diagnosis, and the remaining two patients were referred at the time of relapse. Disease was metastatic at presentation in 4 patients. Radiotherapy was used as a component of primary treatment of disease in 11 patients, in both patients referred for management of local relapse of haemangiopericytoma, and for palliation of metastatic disease developing in 3 patients. One patient received chemotherapy as part of initial treatment. Nine patients have died with survival from first treatment ranging from 3 to 139 months. All 8 surviving patients remain free of disease at 6 to 94 months from first treatment.

Entities:  

Mesh:

Year:  1991        PMID: 1722392     DOI: 10.1111/j.1440-1673.1991.tb03017.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  3 in total

1.  Multiple metastases from a meningeal hemangiopericytoma associated with severe hypoglycemia.

Authors:  Pei Zhou; Masatoshi Kudo; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
Journal:  J Med Ultrason (2001)       Date:  2005-12       Impact factor: 1.314

2.  Treatment of aphakic malignant glaucoma using Nd:YAG laser posterior capsulotomy.

Authors:  B C Little
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

3.  Conjunctival haemangiopericytoma.

Authors:  S Sujatha; R Sampath; R E Bonshek; A B Tullo
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.